Extension of Time to File SOU

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1581 (Rev 09/2005)

OMB No. 0651-0054 (Exp 12/31/2020)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1581 (Rev 09/2005)

OMB No. 0651-0054 (Exp 12/31/2020)

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: RIABNI (see, http://uspto.report/TM/88182290/mark.png)
SERIAL NUMBER: 88182290

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Amgen Inc., having an address of
      Trademark Operations - MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 805-447-3278
      Email: XXXX
Proposed: Amgen Inc., having an address of
      Trademark Operations - MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 805-447-3278
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/05/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

The applicant's current Attorney Information:
      Timothy J. Gaul      Amgen Inc.

      Trademark Operations-MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 805-447-3278
      The docket/reference number is TM-1826-US-1
      Email: tmops@amgen.com


The applicant's proposed Attorney Information:
      Timothy J. Gaul      Amgen Inc.

      Trademark Operations-MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 805-447-3278
      The docket/reference number is TM-1826-US-1
      Email: tmops@amgen.com


Correspondence Information (current):
      Timothy J. Gaul
      PRIMARY EMAIL FOR CORRESPONDENCE: tmops@amgen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): elemoine@amgen.com

Correspondence Information (proposed):
      Timothy J. Gaul
      PRIMARY EMAIL FOR CORRESPONDENCE: tmops@amgen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): elemoine@amgen.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Elsa D. Lemoine/      Date Signed: 10/29/2020
Signatory's Name: Lemoine, Elsa D.
Signatory's Position: Attorney of Record, California Bar member
Signatory's Phone: 805-447-3278

Mailing Address:
   Amgen Inc.
   Trademark Operations-MS-28-5A
   One Amgen Center Drive
   Thousand Oaks, California 91320-1799

RAM Sale Number: 88182290
RAM Accounting Date: 10/29/2020

Serial Number: 88182290
Internet Transmission Date: Thu Oct 29 14:28:09 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XXX-20201029142809
035610-88182290-750918a30f0394c6241cc455
9c326344c63df6341c3ddfc4fce2dd46e6f962ca
5-DA-28054190-20201029071013553584